Vivos Inc Expands Presence with New Subsidiary in India
Vivos Inc Makes Strategic Move to Establish Subsidiary in India
Vivos Inc. (OTCQB: RDGL) has taken a decisive step towards expanding its international operations by authorizing the formation of a wholly owned corporate subsidiary in India. This strategic decision was made to launch Vivos Scientific India LLP, a move aimed at solidifying the company’s commitment to growth in the region as it completes the necessary governmental formalities for approval.
Commitment to International Manufacturing
The establishment of the Indian subsidiary is aimed at creating the company’s first international manufacturing center for its innovative products, including RadioGel and IsoPet. This center will play a critical role in the company's plan to broaden its developmental animal testing capabilities and facilitate the commercial treatment of both humans and animals within the Indian healthcare landscape.
Importance of the Indian Market
India represents a vital corner of the market for Vivos, especially as the company works towards its first in-human trials, which were announced previously. The company is currently engaged in trying to secure approval from the Drug Controller General of India (DCGI) for extended human trials, which would significantly enhance the scope of its medical applications in the region.
FDA Collaboration and Protocol Development
Vivos has indicated that the insights and feedback obtained from the FDA related to their Investigational Device Exemption (IDE) application will inform their formal protocol for the next phases of human trials. These trials will notably incorporate immediate post-treatment PET full-body scans to ensure and validate safety claims surrounding RadioGel.
Leadership Insights on Future Prospects
Michael K. Korenko, Sc.D., the CEO of Vivos Inc, expressed confidence in this strategic decision, stating, "This development demonstrates our long-term commitment to conducting business in India while supporting our objectives to establish a substantive international presence for our innovative treatments." Korenko’s vision for the subsidiary underscores Vivos’s goal of being at the forefront of medical advancements in crucial markets.
Building upon Past Achievements
The significance of the Indian market for Vivos extends beyond initial trial phases. The company believes that the outcomes from the trials conducted in India will not only align with their FDA objectives but further assert their role as pioneers in regenerative health technology.
Contact Information
For more information on the corporate developments, interested parties can contact Michael Korenko at mkorenko@radiogel.com. Vivos Inc is eager to share their journey as they explore new horizons in international healthcare.
Frequently Asked Questions
What new subsidiary is Vivos Inc establishing?
Vivos Inc is establishing a wholly owned subsidiary named Vivos Scientific India LLP in India.
What products will be manufactured in India?
The subsidiary will focus on manufacturing RadioGel and IsoPet, among other products enhancing the company’s offerings.
Why is India a strategic market for Vivos?
India is vital due to ongoing developments in human trials and the potential for expanding treatment options within the region.
What is Vivos Inc’s collaboration with FDA about?
Vivos aims to align trials conducted in India with FDA guidelines to enhance product approval efficacy and safety validation.
How can I learn more about Vivos Inc?
For more details, you can reach out to Vivos Inc through their email or visit their official website.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.